The prostate specific membrane antigen (PSMA) was recognized as promising molecular target and enabled the development of radiolabeled tracer for prostate cancer imaging and endoradiotherapy. Goal of this work was the development and identification of modifications to optimize the pharmacokinetics of ligands based on PSMA I&T. The optimization led to the design of the trimesic acid substituted ligand PSMA-66, which is a remarkably potent tracer with advanced tumor-targeting and pharmacokinetic properties.
«
The prostate specific membrane antigen (PSMA) was recognized as promising molecular target and enabled the development of radiolabeled tracer for prostate cancer imaging and endoradiotherapy. Goal of this work was the development and identification of modifications to optimize the pharmacokinetics of ligands based on PSMA I&T.; The optimization led to the design of the trimesic acid substituted ligand PSMA-66, which is a remarkably potent tracer with advanced tumor-targeting and pharmacokinetic pro...
»